CA2336718A1 - Procedes de traitement de blessures et de troubles neurologiques - Google Patents

Procedes de traitement de blessures et de troubles neurologiques Download PDF

Info

Publication number
CA2336718A1
CA2336718A1 CA002336718A CA2336718A CA2336718A1 CA 2336718 A1 CA2336718 A1 CA 2336718A1 CA 002336718 A CA002336718 A CA 002336718A CA 2336718 A CA2336718 A CA 2336718A CA 2336718 A1 CA2336718 A1 CA 2336718A1
Authority
CA
Canada
Prior art keywords
gdf
fragment
derivative
mammal
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002336718A
Other languages
English (en)
Inventor
Mark Marchionni
Ted Ebendal
Michael Jarpe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cenes Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2336718A1 publication Critical patent/CA2336718A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/48—Nerve growth factor [NGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des procédés de traitement de la mort des cellules nerveuses (dégénération) et des maladies neurodégénératives. Les procédés selon l'invention consistent à administrer une quantité efficace de GDF-1 seul ou en association avec neurotrophine-3 à un patient devant être ainsi traité, par exemple, à une personne ayant eu un accident vasculaire cérébral ou souffrant d'un traumatisme cérébral ou d'une maladie neurodégénérative.
CA002336718A 1998-07-06 1999-07-02 Procedes de traitement de blessures et de troubles neurologiques Abandoned CA2336718A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9179198P 1998-07-06 1998-07-06
US60/091,791 1998-07-06
PCT/US1999/015106 WO2000001440A2 (fr) 1998-07-06 1999-07-02 Procedes de traitement de blessures et de troubles neurologiques

Publications (1)

Publication Number Publication Date
CA2336718A1 true CA2336718A1 (fr) 2000-01-13

Family

ID=22229675

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002336718A Abandoned CA2336718A1 (fr) 1998-07-06 1999-07-02 Procedes de traitement de blessures et de troubles neurologiques

Country Status (6)

Country Link
EP (1) EP1094863A4 (fr)
JP (1) JP2002519394A (fr)
KR (1) KR20010079503A (fr)
AU (1) AU771437B2 (fr)
CA (1) CA2336718A1 (fr)
WO (1) WO2000001440A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1439191T3 (da) * 2004-01-19 2006-08-14 Ares Trading Sa Proces til oprensning af bakterielt udtrykte proteiner
WO2008133141A1 (fr) * 2007-04-24 2008-11-06 Toyo Boseki Kabushiki Kaisha Protéine recombinante d'osmotine, son procédé de fabrication et son utilisation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE184052T1 (de) * 1990-06-15 1999-09-15 Carnegie Inst Of Washington Gdf-1 und uog1 proteine
US5652118A (en) * 1991-03-11 1997-07-29 Creative Biomolecules, Inc. Nucleic acid encoding a novel morphogenic protein, OP-3
US5635372A (en) * 1995-05-18 1997-06-03 Genetics Institute, Inc. BMP-15 compositions
US5767252A (en) * 1996-04-08 1998-06-16 The Johns Hopkins University School Of Medicine Neuronal cell growth factor, Narp

Also Published As

Publication number Publication date
JP2002519394A (ja) 2002-07-02
EP1094863A2 (fr) 2001-05-02
AU5390299A (en) 2000-01-24
EP1094863A4 (fr) 2005-02-02
WO2000001440A2 (fr) 2000-01-13
WO2000001440A3 (fr) 2000-04-20
AU771437B2 (en) 2004-03-25
KR20010079503A (ko) 2001-08-22

Similar Documents

Publication Publication Date Title
AU745324B2 (en) Therapeutic methods comprising use of a neuregulin
EP1364655B1 (fr) Procédé pour favoriser la récupération fonctionnelle de la coordination motrice, de la parole ou de la perception sensorielle à la suite d'une ischemie ou d'un traumatisme du système nerveux central
JP4153036B2 (ja) 截形グリア細胞系由来神経栄養因子
SK65998A3 (en) Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (gdnf) protein product
DE60223511T2 (de) Neurotrophe faktoren
WO2002072005A2 (fr) Conotoxines riches en $g(y)-carboxyglutamate lineaire
US6486122B1 (en) Methods of increasing body weight in a subject by administering TGF-α
EP3173091B1 (fr) Compositions et procede de traitement pendant des periodes non aiguës a la suite de lesion neurologique snc
US6872698B2 (en) Methods for treating neurological injuries and disorders
AU771437B2 (en) Methods for treating neurological injuries and disorders
CN109106943B (zh) 抗癫痫的毒素Martentoxin及其应用
WO1997005893A1 (fr) Remede contre les troubles ophtalmiques
EP1897441A1 (fr) Fragments fonctionnels de TGF-alpha polypeptides et leurs procédés d'utilisation
EP1057489B1 (fr) Utilisation de proteines de la famille des midkines pour le traitement des maladies ischemiques
US20050069537A1 (en) Survical promoting ncam binding and ncam ligand binding compounds
EP0839048A1 (fr) Procede de traitement de l'epilepsie au moyen du facteur neurotrophique derive du cerveau
US20070116702A1 (en) Survival promoting NCAM binding and MCAM ligand binding compounds
US20060172948A1 (en) Gamma-carboxyglutamate containing conopeptides
US20020128193A1 (en) Retro-inverso prosaposin-derived peptides and use thereof
CA2337964A1 (fr) Traitement de l'ischemie ou du traumatisme du systeme nerveux central avec des polypeptides du type facteur de croissance epidermique
Calza et al. Nerve growth factor in the central nervous system: more than neuron survival.
CZ300877B6 (cs) Lécivo pro lécení neurodegenerativních nebo myelinizacních poruch a virový vektor

Legal Events

Date Code Title Description
FZDE Dead